戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 served more than 30 min after removal of the muscarinic receptor agonist.
2 uction following injection of pilocarpine, a muscarinic receptor agonist.
3 s competitively inhibited the binding of the muscarinic receptor agonist, [3H]quinuclidinyl benzilate
4 s in endothelial cells were activated by the muscarinic receptor agonist acetylcholine and an agonist
5 independent, because it is not influenced by muscarinic receptor agonists and antagonists or by treat
6 ing in the presence of low concentrations of muscarinic receptor agonists and following optogenetic a
7 ationship between the efficacy of seven M(3) muscarinic receptor agonists and their rate of dissociat
8           Acetyl-beta-methylcholine (MCh), a muscarinic receptor agonist, applied by either superfusi
9                                              Muscarinic receptor agonists are characterized by appare
10 the L(7) dorsal horn increasing doses of the muscarinic receptor agonist bethanechol, but not the nic
11                                          The muscarinic receptor agonist 'BuTAC' was previously shown
12 e studied for their response to carbachol, a muscarinic receptor agonist, by measuring the increase i
13                                          The muscarinic receptor agonist carbachol activated ERK1/2 b
14                 Here we demonstrate that the muscarinic receptor agonist carbachol activates AMPKalph
15 ted by EGF with those induced by agents (the muscarinic receptor agonist carbachol and thapsigargin (
16 he Ca2+-ATPase inhibitor thapsigargin or the muscarinic receptor agonist carbachol further augmented
17 orylation of Ser-2808 in RyR2 induced by the muscarinic receptor agonist carbachol is mediated by a s
18          Activation of G(i) protein with the muscarinic receptor agonist carbachol protected against
19 ncreased as rapidly as that initiated by the muscarinic receptor agonist carbachol, which promoted an
20 to mediate bronchoconstriction caused by the muscarinic receptor agonist carbachol.
21 tance that was reduced on application of the muscarinic receptor agonist carbachol.
22 trol of the concentration gradient of chosen muscarinic receptor agonists (carbachol, acetylcholine,
23  cells with anti-adrenergic reagents such as muscarinic receptor agonist, carbachol (10(-5)m), or a b
24             At basal 2.8 mmol/l glucose, the muscarinic receptor agonist carbamylcholine chloride (CC
25 ted via sustained delivery of the neurogenic muscarinic receptor agonist cevimeline.
26 (formerly known as KarXT), a novel M(1)/M(4) muscarinic receptor agonist, demonstrated efficacy acros
27 n, we identified a potent and selective M(1) muscarinic receptor agonist from a novel structural clas
28  rat following injection of small amounts of muscarinic receptor agonists into the caudal oral pontin
29 crease in TRPC3-GFP TIRFM in response to the muscarinic receptor agonist methacholine or the syntheti
30                        Spinally administered muscarinic receptor agonists or acetylcholinesterase inh
31                        Spinally administered muscarinic receptor agonists or acetylcholinesterase inh
32 ate post-training intra-BLC infusions of the muscarinic receptor agonist oxotremorine (10 ng/0.2 micr
33 ere bilaterally infused in the NAcc with the muscarinic receptor agonist oxotremorine methiodide (OXO
34                                 Effects of a muscarinic receptor agonist oxotremorine-M (oxo-M) on bl
35  that SPARC enhanced the promoting effect of Muscarinic receptor agonist oxotremorine-M on insulin se
36  RTN chemoreceptors to ACh was mimicked by a muscarinic receptor agonist (oxotremorine; 1 mum), and b
37 tagonist, scopolamine, augments, whereas the muscarinic receptor agonist, oxotremorine, attenuates be
38  currently limited to medications (e.g., the muscarinic receptor agonists pilocarpine and cevimeline)
39 salivation are limited to medications (e.g., muscarinic receptor agonists: pilocarpine and cevimeline
40                 We found that treatment with muscarinic receptor agonist resulted in decreased APP le
41 he APP processing in vivo, we administered a muscarinic receptor agonist (RS86) to normal or aged rat
42 s, we evaluated the ability of the selective muscarinic receptor agonist (SMRA) xanomeline to stimula
43 anomeline is a dual M(1) and M(4)-preferring muscarinic receptor agonist that does not block D(2) dop
44 r to behavioral testing, oxotremorine, an M2 muscarinic receptor agonist that reduces cholinergic rel
45                 Carbachol, a known nAChR and muscarinic receptor agonist, up-regulated both alpha4bet
46        Xanomeline is a dual M1/M4 preferring muscarinic receptor agonist with no direct D2 dopamine r
47 t development of new and highly selective M1 muscarinic receptor agonists with disease-modifying pote
48                                          The muscarinic receptor agonist xanomeline has antipsychotic